RATIONALE: Markers of inflammatory activity are important for assessment and management of many respiratory diseases. Markers that are currently unrecognized may be more valuable than those presently believed to be useful. OBJECTIVES: To identify potential biomarkers of suppurative and inflammatory lung disease in induced sputum samples. METHODS: Induced sputum was collected from 20 healthy control subjects, 24 patients with asthma, 24 with chronic obstructive pulmonary disease, 28 with cystic fibrosis (CF), and 19 with bronchiectasis. Twelve patients with CF had sputum sampled before and after antibiotic therapy for an infective exacerbation. The fluid phase of induced sputum was analyzed by surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectroscopy on three protein array surfaces. Some protein markers were selected for identification, and relevant ELISA assays sought. For 12 patients with CF, both SELDI-TOF and ELISA monitored changes in inflammatory responses during infective exacerbations. MEASUREMENTS AND MAIN RESULTS: SELDI-TOF identified potential biomarkers that differentiated each of the disease groups from healthy control subjects: at a significance of P < 0.01, there were 105 for asthma, 113 for chronic obstructive pulmonary disease, 381 for CF, and 377 for bronchiectasis. Peaks selected for protein identification yielded calgranulin A, calgranulin B, calgranulin C, Clara cell secretory protein, lysosyme c, proline rich salivary peptide, cystatin s, and hemoglobin alpha. On treatment of an infective CF exacerbation, SELDI-TOF determined falls in levels of calgranulin A and calgranulin B that were mirrored by ELISA-measured falls in calprotectin (heterodimer of calgranulins A and B). CONCLUSIONS: Proteomic screening of sputum yields potential biomarkers of inflammation. The early development of a clinically relevant assay from such data is demonstrated.
RATIONALE: Markers of inflammatory activity are important for assessment and management of many respiratory diseases. Markers that are currently unrecognized may be more valuable than those presently believed to be useful. OBJECTIVES: To identify potential biomarkers of suppurative and inflammatory lung disease in induced sputum samples. METHODS: Induced sputum was collected from 20 healthy control subjects, 24 patients with asthma, 24 with chronic obstructive pulmonary disease, 28 with cystic fibrosis (CF), and 19 with bronchiectasis. Twelve patients with CF had sputum sampled before and after antibiotic therapy for an infective exacerbation. The fluid phase of induced sputum was analyzed by surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) mass spectroscopy on three protein array surfaces. Some protein markers were selected for identification, and relevant ELISA assays sought. For 12 patients with CF, both SELDI-TOF and ELISA monitored changes in inflammatory responses during infective exacerbations. MEASUREMENTS AND MAIN RESULTS: SELDI-TOF identified potential biomarkers that differentiated each of the disease groups from healthy control subjects: at a significance of P < 0.01, there were 105 for asthma, 113 for chronic obstructive pulmonary disease, 381 for CF, and 377 for bronchiectasis. Peaks selected for protein identification yielded calgranulin A, calgranulin B, calgranulin C, Clara cell secretory protein, lysosyme c, proline rich salivary peptide, cystatin s, and hemoglobin alpha. On treatment of an infective CF exacerbation, SELDI-TOF determined falls in levels of calgranulin A and calgranulin B that were mirrored by ELISA-measured falls in calprotectin (heterodimer of calgranulins A and B). CONCLUSIONS: Proteomic screening of sputum yields potential biomarkers of inflammation. The early development of a clinically relevant assay from such data is demonstrated.
Authors: Raymond Schipper; Arnoud Loof; Jolan de Groot; Lucien Harthoorn; Eric Dransfield; Waander van Heerde Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2006-10-27 Impact factor: 3.205
Authors: G W Chalmers; K J Macleod; S Sriram; L J Thomson; C McSharry; B H Stack; N C Thomson Journal: Eur Respir J Date: 1999-06 Impact factor: 16.671
Authors: E Pizzichini; M M Pizzichini; A Efthimiadis; S Evans; M M Morris; D Squillace; G J Gleich; J Dolovich; F E Hargreave Journal: Am J Respir Crit Care Med Date: 1996-08 Impact factor: 21.405
Authors: S R Rutgers; T W van der Mark; W Coers; H Moshage; W Timens; H F Kauffman; G H Koëter; D S Postma Journal: Thorax Date: 1999-07 Impact factor: 9.139
Authors: Gordon MacGregor; Robert D Gray; Thomas N Hilliard; Margaret Imrie; A Christopher Boyd; Eric W F W Alton; Andrew Bush; Jane C Davies; J Alastair Innes; David J Porteous; Andrew P Greening Journal: J Cyst Fibros Date: 2008-02-01 Impact factor: 5.482
Authors: Philip A Reid; David A McAllister; A Christopher Boyd; J Alastair Innes; David Porteous; Andrew P Greening; Robert D Gray Journal: Am J Respir Crit Care Med Date: 2015-01-15 Impact factor: 21.405
Authors: Lauren D Palmer; K Nichole Maloney; Kelli L Boyd; A Kasia Goleniewska; Shinji Toki; C Noel Maxwell; Walter J Chazin; R Stokes Peebles; Dawn C Newcomb; Eric P Skaar Journal: Am J Respir Cell Mol Biol Date: 2019-10 Impact factor: 6.914
Authors: Dinesh K Pillai; Binu-John V Sankoorikal; Eric Johnson; Angelo N Seneviratne; Jessica Zurko; Kristy J Brown; Yetrib Hathout; Mary C Rose Journal: Am J Respir Cell Mol Biol Date: 2014-02 Impact factor: 6.914
Authors: Melania D'Orazio; Maria Chiara Mastropasqua; Mauro Cerasi; Francesca Pacello; Ada Consalvo; Barbara Chirullo; Brittany Mortensen; Eric P Skaar; Domenico Ciavardelli; Paolo Pasquali; Andrea Battistoni Journal: Metallomics Date: 2015-06 Impact factor: 4.526
Authors: Ida Chiara Guerrera; Giuseppe Astarita; Jean-Philippe Jais; Dorota Sands; Anna Nowakowska; Julien Colas; Isabelle Sermet-Gaudelus; Martin Schuerenberg; Daniele Piomelli; Aleksander Edelman; Mario Ollero Journal: PLoS One Date: 2009-11-06 Impact factor: 3.240